Bladder Cancer Pipeline

DelveInsight’s, “Bladder Cancer Pipeline Insight, 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Bladder Cancer Understanding

Bladder Cancer Overview

Bladder cancer is a malignant condition in which abnormal cells grow uncontrollably in the tissues of the urinary bladder, most commonly in the urothelial cells lining the inside of the bladder. Urothelial carcinoma (transitional cell carcinoma) is the most common type, accounting for the majority of bladder cancer cases. The disease may remain confined to the bladder lining (non–muscle-invasive bladder cancer) or invade deeper muscle layers and spread to other organs (muscle-invasive or metastatic bladder cancer). Common symptoms include blood in the urine (hematuria), painful urination, urinary urgency, and pelvic pain.

The exact cause of bladder cancer is multifactorial and involves both environmental and genetic factors. Cigarette smoking is the strongest risk factor and is responsible for nearly half of all cases because tobacco carcinogens are excreted into the urine and damage bladder cells. Other causes and risk factors include occupational exposure to chemicals such as aromatic amines used in dye, rubber, leather, and paint industries, chronic bladder irritation and infections, exposure to arsenic in drinking water, previous chemotherapy or pelvic radiation and increasing age. Genetic mutations accumulated over time also contribute to malignant transformation of bladder epithelial cells.

Bladder cancer develops through progressive genetic and molecular alterations in urothelial cells that lead to uncontrolled cell proliferation and tumor formation. Carcinogens present in urine repeatedly contact the bladder lining, causing DNA damage and mutations in tumor suppressor genes and oncogenes such as TP53, FGFR3, and RB1. These molecular changes disrupt normal regulation of cell growth, apoptosis, and differentiation, leading to the formation of papillary or invasive tumors. Non-muscle-invasive tumors tend to recur frequently, whereas muscle-invasive disease has a higher potential for metastasis through lymphatic and hematogenous spread.
Diagnosis of bladder cancer begins with clinical evaluation and urine testing, especially in patients presenting with hematuria. Diagnostic procedures include urinalysis, urine cytology, cystoscopy, and biopsy of suspicious lesions. Cystoscopy is considered the gold standard because it allows direct visualization of the bladder interior and tissue sampling. Imaging studies such as CT urography, MRI, ultrasound, and PET scans may be used to determine tumor extent and metastasis. Histopathological examination confirms the diagnosis and helps determine tumor grade and stage, which guide treatment decisions.

Treatment depends on the stage, grade, and extent of disease. Non-muscle-invasive bladder cancer is commonly treated with transurethral resection of bladder tumor (TURBT) followed by intravesical therapy such as Bacillus Calmette-Guérin (BCG) immunotherapy or intravesical chemotherapy to reduce recurrence risk. Muscle-invasive bladder cancer often requires radical cystectomy combined with chemotherapy, radiation therapy, or immunotherapy. Advanced or metastatic bladder cancer may be treated with systemic chemotherapy, immune checkpoint inhibitors, antibody-drug conjugates, or targeted therapies depending on molecular characteristics. Early diagnosis and regular surveillance are important because recurrence rates are high..

"Bladder Cancer Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bladder Cancer pipeline landscape is provided which includes the disease overview and Bladder Cancer treatment guidelines. The assessment part of the report embraces, in depth Bladder Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bladder Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Bladder Cancer Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Bladder Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Bladder Cancer. 

Bladder Cancer Emerging Drugs Analysis

This segment of the Bladder Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bladder Cancer Emerging Drugs

Cretostimogene grenadenorepvec: CG Oncology

Cretostimogene grenadenorepvec is an investigational intravesically delivered oncolytic immunotherapy developed by CG Oncology for bladder cancer. The drug is a genetically engineered adenovirus designed to selectively replicate in and destroy retinoblastoma pathway–defective bladder tumor cells while simultaneously stimulating anti-tumor immune responses through granulocyte-macrophage colony-stimulating factor (GM-CSF) expression. Its mechanism of action involves direct oncolysis of tumor cells combined with activation of local and systemic immune-mediated anti-cancer activity. The U.S. FDA has granted both Fast Track Designation and Breakthrough Therapy Designation to cretostimogene grenadenorepvec for high-risk BCG-unresponsive NMIBC. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Bladder Cancer.

Erda-iDRS: Johnson & Johnson

Erda-iDRS is an investigational intravesical drug-releasing system, the therapy is designed to provide prolonged local delivery of erdafitinib, a fibroblast growth factor receptor (FGFR) kinase inhibitor, directly into the bladder over an extended period. Its mechanism of action in bladder cancer involves selective inhibition of FGFR alterations, which are commonly associated with tumor growth and recurrence in non–muscle-invasive bladder cancer (NMIBC), while minimizing systemic exposure through localized intravesical administration. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Bladder Cancer.

MK-1022: Merck & Co.

MK-1022 is an investigational antibody-drug conjugate (ADC) being developed by Merck & Co. The drug consists of a fully human anti-HER3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload. Its mechanism of action in bladder cancer involves targeting HER3-expressing tumor cells, followed by internalization of the ADC and intracellular release of the cytotoxic topoisomerase I inhibitor, resulting in DNA damage and tumor cell death. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Bladder Cancer.

STM-416: SURGE

STM-416 is an investigational intraoperative immunotherapy for the treatment of recurrent high-grade non-muscle-invasive bladder cancer (NMIBC). The drug is a biodegradable hydrogel formulation containing resiquimod, a Toll-like receptor 7/8 (TLR7/8) agonist, designed for sustained local release at the tumor resection site following transurethral resection of bladder tumor (TURBT). STM-416 works by activating innate and adaptive immune responses through TLR7/8 signaling, thereby promoting anti-tumor activity and helping prevent bladder cancer recurrence and progression after surgery. Currently, the drug is being evaluated in the Phase I/II stage of its development 
for the treatment of Bladder Cancer.

SL-28: Second Life Therapeutics

SL-28 is an investigational allogeneic, non-genetically modified cell therapy being developed by Second Life Therapeutics for advanced solid tumors, including bladder cancer. The mechanism of action of SL-28 involves TezR-modified donor leukocytes engineered through modulation of the Universal Receptive System and Cell Memory, which activates multiple anticancer pathways including immune cell signaling, migration, endocytosis, phagocytosis, and energy metabolism to promote tumor destruction. In bladder cancer, SL-28 is intended to target resistant genitourinary tumors through enhanced immune-mediated anticancer activity. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Bladder Cancer.

IAM1363: Iambic Therapeutics, Inc

IAM1363 is an investigational small-molecule, brain-penetrant HER2 tyrosine kinase inhibitor. The drug is designed to selectively inhibit both wild-type and oncogenic mutant HER2 proteins while sparing EGFR, thereby reducing EGFR-related toxicities commonly associated with pan-ERBB inhibitors. In bladder cancer, IAM1363 targets HER2-driven tumor signaling pathways that promote cancer cell proliferation, survival, and metastasis. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Bladder Cancer.

Further product details are provided in the report……..

Bladder Cancer Drug Therapeutic Assessment

This segment of the report provides insights about the different Bladder Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Bladder Cancer Players in Bladder Cancer

There are approx. 80+ key companies which are developing the therapies Bladder Cancer. The companies which have their Bladder Cancer drug candidates in the most advanced stage, i.e. Phase III include, CG Oncology, Inc. and others.

Bladder Cancer Clinical Trial Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Bladder Cancer Drug Route of Administration

Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Bladder Cancer Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Bladder Cancer Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bladder Cancer Clinical Trial Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bladder Cancer therapeutic drugs key players involved in developing key drugs. 

Bladder Cancer Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bladder Cancer drugs.

Bladder Cancer Report Insights

• Bladder Cancer Pipeline Analysis
• Bladder Cancer Therapeutic Assessment
• Bladder CancerUnmet Needs
• Impact of Bladder Cancer Drugs

Bladder Cancer Pipeline Report Assessment

• Bladder Cancer Pipeline Product Profiles
• Bladder Cancer Therapeutic Assessment
• Bladder Cancer Pipeline Assessment
• Bladder Cancer Inactive drugs assessment
• Bladder Cancer Market Unmet Needs

Key Questions Answered In the Bladder Cancer Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Bladder Cancer drugs?
• How many Bladder Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bladder Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bladder Cancer therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Bladder Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Bladder Cancer Key Players

• CG Oncology, Inc.
• Johnson & Johnson
• Eli Lilly and Company
• Relmada Therapeutics, Inc.
• Protara Therapeutics
• Theralase® Technologies Inc.
• Tyra Biosciences, Inc
• Bristol-Myers Squibb
• Merck & Co., Inc
• Molecular Partners AG 
• Aura Biosciences
• BioNTech SE
• Tasca Therapeutics
• Iambic Therapeutics, Inc
• Eli Lilly and Company
• Monopar Therapeutics
• Pilatus Biosciences Inc
• Second Life Therapeutics
• SURGE Therapeutics

Bladder Cancer Key Products

• Cretostimogene Grenadenorepvec 
• Erda-iDRS
• Vepugratinib
• NDV-01 
• TARA-002
• TLD-1433
• TYRA-300
• Iza-bren
• MK-5909
• MK-1022
• V940
• [212Pb]Pb-MP0712
• AU-011 
• BNT329 
• CP-383 
• intismeran autogene
• MK-3120
• IAM1363
• LY4052031
• MNPR-101-PCTA-177Lu 
• PLT012 
• SL-28
• STM-416